BITS Pilani
Pilani | Dubai | Goa | Hyderabad | Mumbai
An Institution of Eminence

विज्ञान एवं प्रौद्योगिकी विभाग
DEPARTMENT OF
SCIENCE & TECHNOLOGY
सत्यमेव जयते

BITS Pilani
TECHNOLOGY
ENABLING
CENTRE
DST Supported

GRANTED

(IN413180) Novel oxazolidine compound and method of its preparation



NEED

Tuberculosis (TB) remains one of the deadliest infectious diseases globally, with treatment resistance and insufficient drug targets. A novel approach targeting GlmUMtb, a key enzyme in Mycobacterium tuberculosis, could change TB treatment.

MARKET ANALYSIS

The global tuberculosis market is projected to grow at a CAGR of 5.8% from 2023 to 2033, driven by increasing TB incidence and the demand for effective, novel treatments. (Source: Market Research Future, 2023)

TECHNOLOGY OVERVIEW

This patent introduces an oxazolidine compound that inhibits GlmUMtb, a critical enzyme in Mycobacterium tuberculosis. By disrupting the synthesis of key metabolites essential for bacterial survival, it offers a promising new treatment for tuberculosis, targeting both in vivo and in vitro infections.

Target Industries

1) Pharmaceutical companies developing TB treatments; 2) Research institutions focused on drug discovery; 3) Biotechnology firms working on novel antibiotic development; 4) Healthcare providers focused on infectious diseases.

TECHNOLOGY KEY FEATURES

Oxazolidine compound; inhibits GlmUMtb enzyme; disrupts key metabolic intermediates; high binding affinity; potential treatment for tuberculosis; novel drug target for TB.

AT A GLANCE

- SDG 3 (Good Health and Well-being), SDG 9 (Industry, Innovation, and Infrastructure), SDG 10 (Reduced Inequality)

Read more here

Technology is available for licensing/ co-development.

Reach out to Prof. Deepak Chitkara, Coordinator, BITS Technology Enabling Centre,
BITS Pilani Contact Details: tec.bits@pilani.bits-pilani.ac.in, 91 1596-255913

innovate achieve lead